Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Find out various ways to enhance your cash back while grocery shopping. Boost your savings effortlessly with these tips.
28,120 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
This guide compares two popular bond ETFs—Fidelity Bond ETF (FIGB) and IEI—focusing on yield, fees, and risk. Learn p...
With the Fed continuing its easing drive in 2026, savers face a key choice between a HYSA and a CD. This report break...
Looking for growth you can ride for years? This guide breaks down three powerhouse names—NVIDIA, Microsoft, and Alpha...
A top executive leaves Bitcoin Depot as regulators tighten the screws on crypto kiosks. The move highlights how the c...
AI infrastructure is booming, but spending fears linger. This piece highlights two credible stock picks that could ri...
Two Nasdaq-100 trackers offer the same index path, but a small fee delta has produced a 6.86% trailing return gap ove...
Long-term savers are turning to reliable income streams. Three dividend ETFs stand out for 2026, balancing yield, qua...
When a company director sells a large block of stock, it can raise questions. This guide explains what signals to wat...
NVDY's option-income approach pays steady income but caps upside, leading nvdy investors to miss half of NVIDIA's exp...
Strategy disclosed a new Bitcoin sale as part of its renewed capital plan. Far from signaling weakness, the move coul...
Global security priorities and rising defense budgets spotlight the best aerospace defense stocks. Here’s a timely lo...